The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Urol. 2016 Nov;196(5):1356-1362. doi: 10.1016/j.juro.2016.04.073. Epub 2016 Apr 30.
To our knowledge quality of life has not been evaluated in rigorous fashion in patients undergoing active surveillance for small renal masses. The prospective, multi-institutional DISSRM (Delayed Intervention and Surveillance for Small Renal Masses) Registry was opened on January 1, 2009, enrolling patients with cT1a (4.0 cm or less) small renal masses who elected primary intervention or active surveillance.
Patients were enrolled following a choice of active surveillance or primary intervention. The active surveillance protocol includes imaging every 4 to 6 months for 2 years and every 6 to 12 months thereafter. The SF12® quality of life questionnaire was completed at study enrollment, at 6 and 12 months, and annually thereafter. MCS (Mental Component Summary), PCS (Physical Component Summary) and overall score were evaluated among the groups and with time using ANOVA and linear regression mixed modeling.
At 82 months among 3 institutions 539 patients were enrolled with a mean ± SD followup of 1.8 ± 1.7 years. Of the patients 254 were on active surveillance, 285 were on primary intervention and 21 were on active surveillance but crossed over to delayed intervention. A total of 1,497 questionnaires were completed. Total and PCS quality of life scores were better for primary intervention at enrollment through 5 years. There were generally no differences in MCS scores among the groups and there was a trend of improving scores with time.
In a prospective registry of patients undergoing active surveillance or primary intervention for small renal masses those undergoing primary intervention had higher quality of life scores at baseline. This was due to a perceived benefit in the physical health domain, which persisted throughout followup. Mental health, which includes the domains of depression and anxiety, was not adversely affected while on active surveillance, and it improved with time after selecting a management strategy.
据我们所知,在接受小肾癌主动监测的患者中,尚未以严谨的方式评估生活质量。前瞻性、多机构 DISSRM(小肾癌延迟干预和监测)注册研究于 2009 年 1 月 1 日开放,纳入了选择主动监测或初始干预的 cT1a(≤4.0cm)小肾癌患者。
患者在选择主动监测或初始干预后入组。主动监测方案包括前 2 年每 4-6 个月进行一次影像学检查,此后每 6-12 个月进行一次。SF12®生活质量问卷在研究入组时、6 个月和 12 个月时以及此后每年进行一次评估。采用方差分析和线性回归混合模型评估各组之间以及随时间推移的 MCS(心理成分综合评分)、PCS(躯体成分综合评分)和总评分。
在 3 家机构的 82 个月随访中,共纳入 539 例患者,平均随访时间为 1.8±1.7 年。254 例患者接受主动监测,285 例患者接受初始干预,21 例患者接受主动监测但转为延迟干预。共完成 1497 份问卷。在入组时至 5 年,初始干预组的总评分和 PCS 生活质量评分均较高。各组之间的 MCS 评分一般无差异,且随时间推移呈改善趋势。
在小肾癌主动监测或初始干预患者的前瞻性登记研究中,初始干预组在基线时的生活质量评分较高。这是由于在身体健康方面存在获益,这种获益在随访过程中持续存在。在接受主动监测时,心理健康(包括抑郁和焦虑领域)并未受到不利影响,并且在选择管理策略后随时间推移而改善。